I am a physician board-certified in pediatrics, gastroenterology, and transplant hepatology with a career dedicated to pediatric hepatology and liver transplantation. The primary focus of my scholarly work is in Clinical Expertise and Innovation, with a Significant Supporting Activity in Investigation. My training has been extensive and international, with significant experience in India, the UK, and the US. After completing medical school in Calcutta and pediatric training in Bombay, I specialized in pediatrics and hepatology at King’s College Hospital, London, Europe’s largest liver transplant center. During my seven-year fellowship, I also conducted research at University College London, earning a Doctor of Medicine degree for my work on autoimmune hepatitis. Since being recruited to the United States in 2002, I have held leadership positions at Mount Sinai Medical Center, Children’s Hospital Los Angeles (CHLA), and the University of Rochester, developing and expanding pediatric liver transplant programs. In 2023, I was recruited to the Massachusetts General Brigham for Children as the Section Chief of Pediatric Hepatology & Liver Transplant and the Medical Director of the Hepatobiliary Program. For over 20 years, I have been a clinical leader in pediatric liver disease and transplantation, establishing and directing liver transplant programs at major medical centers across the US. My clinical expertise in autoimmune hepatitis has contributed to the development of international guidelines as one of two pediatric hepatologists invited to co-author the American Association for the Study of Liver Diseases (AASLD) guidelines on autoimmune hepatitis, I have helped shape global best practices in managing this condition. I also serve as the Primary Physician for the Pediatric Liver Transplant Program for the United Network of Organ Sharing at MGH and represent MGH on the National Liver Review Board for Pediatrics. As a pediatrician at Kings College Hospital in London, I was involved in the first description of ‘de novo’ autoimmune hepatitis after liver transplantation, a pivotal discovery published in The Lancet, which brought worldwide recognition to this condition in pediatric liver transplant recipients. Having described the condition of ‘de novo’ autoimmune hepatitis in pediatric liver transplant recipients, I expanded my work in autoimmune liver disease through several areas of investigation. I developed an ELISA to detect liver kidney microsomal antibodies and used this assay to perform epitope mapping studies, providing data on the role of molecular mimicry in the pathogenesis of autoimmune hepatitis. After moving to the US, my clinical innovation has focused on improving adherence and transition to adult programs for pediatric patients with autoimmune hepatitis, as well as using novel combinations of immunosuppressants to treat refractory cases of AIH after liver transplantation. At Mount Sinai and CHLA, I played a key role in building multidisciplinary liver transplant teams and launching successful programs with excellent clinical outcomes. Most recently, I helped establish the safety and efficacy of administering live vaccines to immunosuppressed pediatric liver transplant recipients, which has led to changes in clinical practice for this vulnerable group of patients. Currently, at Massachusetts General Hospital for Children, I lead the Hepatobiliary Program and the Pediatric Liver Transplant Program, where I continue to expand clinical services and improve patient outcomes. Through this work, I have been heavily invested in highly collaborative efforts that have advanced the field of pediatric hepatology and pediatric transplant hepatology. I served as a co-investigator for over 10 years and as a site PI for the NIDDK-funded Childhood Liver Disease Research and Education Network (ChiLDReN), contributing to studies such as the BASIC (Biliary Atresia Study in Infants and Children) and LOGIC (Longitudinal Study of Genetic Cause of Intrahepatic Cholestasis) trials. These efforts have led to publications in high-impact journals. I also participated in the early ITCH, IMAGINE, and INDIGO studies, which explored the safety and efficacy of apical bile salt uptake inhibitors in cholestatic disorders. These treatments have since received FDA approval for alleviating pruritus in children with Alagille syndrome and bile acid transport defects. Additionally, I have been the site PI for multicenter consortia studies on pediatric acute liver failure, pediatric fatty liver disease, and PSC (Primary Sclerosing Cholangitis). My work with the Society of Pediatric Liver Transplantation (SPLIT) has contributed to understanding medication adherence in pediatric liver transplant recipients. I have been invited to speak on regional, national, and international stages more than 100 times, including Grand Rounds presentations at leading pediatric hospitals across the country. I have chaired numerous sessions at annual meetings of the AASLD and served as an expert in multiple “Meet the Expert” sessions. I was elected to the American Pediatric Society in 2014 and have served on several prestigious committees, including the Abstract Review Committee for Digestive Disease Week (DDW) and the AASLD Abstract Review Committee, which I chaired from 2021-2024. My scholarly contributions include 94 peer-reviewed manuscripts, 23 case reports with mentees, 28 peer-reviewed chapters, reviews, editorials, and two books.